<DOC>
	<DOCNO>NCT02692105</DOCNO>
	<brief_summary>This study offer men intermediate risk prostate cancer suitable , interested , prostate brachytherapy , opportunity randomize low dose rate ( LDR ) brachytherapy use permanent implantation radioactive seed ( current standard care BC ) high dose rate ( HDR ) temporary brachytherapy also available standard care BC use boost addition external beam radiotherapy . In addition , men offer opportunity test aggressiveness cancer use Cell Cycle Progression Gene Profile .</brief_summary>
	<brief_title>Comparison HDR vs. LDR Brachytherapy Monotherapy Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>Purpose : To conduct Phase III randomize trial favorable tier intermediate risk prostate cancer select favorable risk tumor evaluate difference Quality Life urinary domain LDR HDR brachytherapy . Hypothesis : Because rapid dose delivery HDR compare LDR brachytherapy ( 15 minute vs. 6 month ) precise control dose adjacent critical structure ( prostatic bulbo-membranous urethra anterior rectal wall ) , HDR prostate brachytherapy associate rapid recovery acute symptom favorable side effect protocol use boost combination external beam radiotherapy . The hypothesis advantage maintain brachytherapy use monotherapy without addition external beam radiation . Justification : In British Columbia , LDR prostate brachytherapy current standard select men favorable risk prostate cancer suitable , willing accept active surveillance , men favorable intermediate risk prostate cancer . LDR brachytherapy available BC 15 year highly effective 7-year biochemical disease-free rate ~95 % . However , type treatment prolonged recovery phase return baseline urinary function take 6 12 month . This partly due fact radiation deliver 6 month period implant seed , partly due uncertainty final seed placement . HDR brachytherapy advantage deliver treatment rapidly 15-20 minute , also exploit radiobiologic nature prostate cancer responsive large dos radiotherapy . Experience use HDR brachytherapy boost show much reduce impact quality life . Objectives : Primary : To evaluate difference QOL urinary domain LDR HDR brachytherapy use urinary domain EPIC prostate cancer specific QOL questionnaire . Secondary : - To assess difference bowel sexual domain EPIC prostate cancer specific QOL questionnaire 2 treatment - To asses time recovery IPS Score widely use assess urinary function prostate cancer treatment . The time return baseline +/- 3 point determine . - Acute long-term toxicity grade use Common Terminology Criteria Adverse Events ( CTCAE V4 ) follow time point - TRUS- MRI fusion develop within plan software facilitate treatment plan - To assess treatment efficacy , PSA record every 6 month 5 year annually 10 year prostate re-biopsy perform 36 month radiotherapy . Optional : For patient consent targeted biopsy anaesthesia start brachytherapy procedure ( separate consent ) - Verify MRI-TRUS fusion accuracy - Correlate Cell Cycle Progression score outcome . Research Method : Multiparametric MRI ( mpMRI ) perform men stag procedure ensure appropriateness brachytherapy monotherapy ( without addition external beam radiotherapy hormone therapy ) . The value mpMRI stag prostate cancer widely recognize . Previous study show 90 % intermediate risk cancer visible mpMRI . The MR image fuse plan trans rectal ultrasound ( TRUS ) patient , ensure adequate dose coverage lesion . For patient consent optional biopsy anesthesia , accuracy fusion verify obtain 2 biopsy visualize lesion TRUS guidance start brachytherapy procedure . Follow per standard practice ass urinary , bowel sexual side effect . In addition standard form , patient also complete EPIC questionnaire . The questionnaire complete every 3 month 1 year every 6 month 3 year annually , per standard follow schedule . Once biopsy material pathologically confirm contain target lesion , aggressiveness assess Cell Cycle Progression ( CCP ) Gene Profile test . Men may randomize type brachytherapy decline biopsy . This initial protocol Pilot test feasibility randomization ( patient acceptance ) . The aim accrue 60 men 18-24 month achieve apply expand total 200 men .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Clinical stage T1cT2b , PSA &lt; 20 , Gleason &lt; 8 ECOG 01 Low tier intermediaterisk prostate cancer define ; single NCCN intermediate risk factor ( either Gleason 7 ( 3+4 ) PSA &lt; 10 ng/ml OR Gleason 6 PSA 1020 ng/ml ) Extensive favorablerisk disease define : clinical stage T1cT2a PSA &lt; 10 Gleason 6 ≥ 50 % biopsy core contain cancer PSA density &gt; 0.2 ng/cc Selected intermediate risk patient define T1c/T2a PSA &lt; 10 Gleason 4+3 &lt; 33 % core involve Max tumour length core 10 mm No androgen deprivation therapy ( ADT ) Prostate volume TRUS ≤ 60 cc . Not eligible , accept , active surveillance accord NCCN guideline . Signed study specific inform consent . Prior radical surgery carcinoma prostate , Prior pelvic radiation Prior chemotherapy prostate cancer , Prior TURP cryosurgery prostate Claustrophobic unable undergo MRI</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>prostate adenocarcinoma</keyword>
	<keyword>intermediate risk group</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>High Dose Rate vs Low Dose Rate</keyword>
	<keyword>Quality Life</keyword>
</DOC>